AVP
In the context of the launch of its Late Stage Fund, AVP continues to strengthen its leadership team to reinforce its global platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502656787/en/
(Photo: Business Wire)
First, after the recruitment of Elizabeth de Saint-Aignan in the USA, Warda's appointment in Europe completes the senior team of the new AVP Late Stage Fund.
Prior to joining AVP, Warda Shaheen held the position of Director at OMERS Growth Equity, where she conducted investments in prominent software companies such as Coveo, TouchBistro, PandaDoc, Clio, Celigo and GitLab. Previously, Warda worked in public markets at CPP Investments where she ran a $500M public markets portfolio in the thematic investing team. She also worked at Point72 Asset Management, Bain & Company and Deutsche Bank. Warda has experience working in the United States, Canada, United Kingdom, Singapore, Hong Kong and Germany. Warda holds an MSc in Financial Economics from the University of Oxford, a BESc in Mechanical Engineering from the University of Western University and an HBA in Business Administration the Richard Ivey School of Business.
Second, Pedro's appointment as Partner in charge of investor relations underlines AVP's objective of managing more capital for top tier institutional investors. Pedro brings extensive experience in fundraising of technology funds, from his tenure at Target Global, where he played a key role in fundraising multiple tech funds and fostering investor relationships. He has also held senior positions at MVision and Hamilton Lane. Having started his career in the venture capital arm of FINEP, the Brazilian innovation agency, Pedro holds an MBA and a BSc in Industrial Engineering from Pontifícia Universidade Católica do Rio de Janeiro.
“On behalf of the AVP team, I am delighted to extend a warm welcome to Warda and Pedro as our newest Partners. I am also very proud that AVP can attract such talents, and in the case of Warda, convince top tier investor in the North American market to come to Paris. Warda will play a key role in developing our new Late Stage Fund strategy, focusing on Europe. With this new Late Stage fund, we now have the capability to support entrepreneurs throughout their journey, from the early stages to IPO, as well as post-IPO, which sets us apart in the market. Warda brings extensive knowledge and a proven track record in investing in Late Stage companies in the US and in Europe. In the context of our platform expansion and ongoing fundraising efforts across various strategies, we are very happy to benefit from Pedro’s substantial fundraising experience of technology focused fund. His background at Target Global will undoubtedly add value to the entire AVP platform. At AVP, nothing is more important than the quality, the diversity and the complementarity of the team. Since 8 years, we have welcomed 9 Partners and are now ready to further expand the team with these two talents. No doubt that they will play a key role in the next chapter of our journey," commented François Robinet, Managing Partner at AVP.
“I am thrilled to become a part of the outstanding team of investors at AVP. Since I was introduced to the firm, I recognized this platform had the vision, skills, and leadership to amplify the global landscape of technology investing with a diverse partnership that leverages expertise across the financing spectrum. AVP's Late Stage strategy in Europe addresses several challenges in the European ecosystem, including the shortage of local funding for exceptional European technology leaders to expand globally. At AVP, we look forward to bringing our collective knowledge to support such leaders at various stages in both the private and public markets,” commented Warda Shaheen, General Partner at AVP.
“I am excited to join an incredibly talented team of investor at AVP. I have been fortunate to follow the development of the platform over the years and, now as part of the team, look forward to develop their robust capital base to attract additional top tier institutional investors globally,” commented Pedro Barros, Partner at AVP.
About AVP (AXA Venture Partners)
AVP (AXA Venture Partners) is a global venture capital firm specializing in high-growth, technology- enabled companies, managing more than $2 billion in assets across four investment strategies: Venture, Growth, Late Stage, and Fund of Funds. Since its establishment in 2016, AVP has invested in more than 60 technology companies in Venture and Growth stages in the US and Europe.
With offices in New York, London, and Paris, AVP supports companies in expanding internationally and provides portfolio companies with tailored business development opportunities to further accelerate their growth. AVP operates under AXA IM- Alts, the alternative investment business unit of AXA IM.
For more information, visit axavp.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502656787/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thredd Powers Successful Migration of BigPay’s Card Portfolio to Next-Gen Platform26.11.2025 09:00:00 CET | Press release
The transition of millions of cards showcases Thredd’s superior capabilities amid a high-stakes, global trend of sunsetting legacy processing engagements Thredd, the leading next-generation global payments processor, has successfully migrated BigPay’s virtual and physical card portfolio from its previous, legacy processor to Thredd’s next-generation platform, underscoring Thredd’s leadership in complex card portfolio migrations. The migration project, one of several in recent years, included over 2.5 million cards and highlights Thredd’s unique combination of deep migration experience, robust processes, and advanced technology—qualities increasingly critical as the industry faces a wave of modernisation and replatforming. This achievement comes at a pivotal moment for the industry. Industry analysts estimate that retail banks failing to modernise could see 10% to 15% of their payments revenue at risk annually as legacy platforms struggle to keep pace with demands for hyperpersonalizati
With Two in Five Employees Undergoing Fertility Treatment Leaving Their Jobs or Considering Quitting, Are Companies Doing Enough?26.11.2025 08:00:00 CET | Press release
An international survey, spanning Australia, France, Japan, Poland and the UK, has found that many employees experiencing fertility challenges lack support in the workplace, with almost two in five (39%) leaving or considering leaving their roles while undergoing treatment.1 ‘The Impact of Fertility Challenges at Work: International Insights’ survey by Ferring Pharmaceuticals, Fertility Matters at Work and This Can Happen shows that, despite growing awareness of reproductive health, two thirds (67%) who have experienced fertility challenges say that their workplaces do not offer support for employees undergoing fertility treatment, with France the least likely to provide it (88%).1 60% said they were not clearly entitled to time off for fertility appointments, with time recorded as paid leave, unpaid leave or annual leave (26%), and some also reported taking sick leave due to a lack of flexibility (17%).1 With assisted reproduction therapy, including IVF, already accounting for up to 1
Venture Global and Tokyo Gas Announce 20-Year LNG Sales and Purchase Agreement26.11.2025 01:00:00 CET | Press release
Venture Global’s fourth long-term contract with a Japanese company7.75 MTPA of long-term contracts signed by Venture Global to date in 2025 Today, Venture Global, Inc. (NYSE: VG) and Tokyo Gas Co., Ltd announced the execution of a new, long-term liquefied natural gas (LNG) Sales and Purchase Agreement (SPA). Under the SPA, Tokyo Gas will procure 1 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2030. This deal marks 7.75MTPA of SPAs signed by Venture Global in the last six months. “With nearly 8 MTPA of new long-term commitments signed this year, Venture Global is pleased to build on our commercial momentum through this new partnership with Tokyo Gas,” said Venture Global CEO Mike Sabel. “Tokyo Gas is a pioneer in the LNG industry and leading provider of natural gas to Japan, and we look forward to working with them as we grow our position as a top LNG supplier to Japan. This agreement will contribute significantly to the US-Japan balance of trade o
Airship Study: No-Code Native App Experiences Double Purchase Frequency (+140%), Offering Path to Profitable Holiday Growth26.11.2025 00:08:00 CET | Press release
New research quantifies the massive conversion lift from optimizing native app and web experiences, providing a critical no-code path for retailers to drive profitability Mobile-first customer experience company Airship today released new aggregate data analysis findings showing that no-code native app experiences significantly increase conversion for key lifecycle events and more than double purchase frequency. The Airship "Experience Impact” research, which studied over 1,000 in-app retail experiences and 1.7 billion device sessions, quantifies the impact of optimizing end-to-end customer journeys—not just sending messages—using no-code and AI-powered tools to drive loyalty and retention at scale, leading to sustainable profitability in a volatile economic environment. Key Findings Customers exposed to high-impact no-code native app experiences such as optimized onboarding flows, dynamic surveys, or embedded personalized offers, purchase 140% more frequently than app customers who do
Court Finds That Two Advanced Cell Diagnostics Patents Are Not Infringed by Molecular Instruments’ Proprietary HCR™ RNA-ISH Technology25.11.2025 17:30:00 CET | Press release
Molecular Instruments, Inc. announced today that the Unified Patent Court (UPC) of the European Union has found that Molecular Instruments’ HCR™ RNA-ISH technology does not infringe two patents owned by Advanced Cell Diagnostics, Inc. (a Bio-Techne group company). In a 2024 lawsuit filed in the UPC (proceedings no. UPC CFI 187/2024), Advanced Cell Diagnostics alleged that Molecular Instruments’ HCR™ RNA-ISH technology infringes European patents (EP) 2,500,439 and 1,910,572. The Court in its judgment of 18 November 2025 has rejected that claim and dismissed all of Advanced Cell Diagnostics' lawsuit, ruling that the patents are not infringed either literally or by equivalence (UPC Judgment). This 2025 UPC judgment follows on the heels of an April 2024 UK judgment in which the High Court of England and Wales had already dismissed an earlier infringement lawsuit by revoking the UK parts of the same two Advanced Cell Diagnostics patents (proceedings no. HP-2022-000026), ruling that they wer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
